CME/CE

Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data bring these concepts to life, with special attention to application in VA and academic settings. Whether you're a medical oncologist, ocular oncologist, ophthalmologist, or APP, this discussion is designed to sharpen your skills and your care aligned with the latest science.

Are you up to date on treatment strategies for young adults with acute lymphoblastic leukemia (ALL)? Evolving evidence and clinical guidelines now strongly support the use of asparaginase-based, pediatric-inspired regimens over traditional adult protocols for young adults with ALL. However, many patients continue to be treated with adult protocols that lack asparaginase and are associated with poorer outcomes. In this dynamic, case-based activity, celebrity advocates Rob Benedict and Abbie Cobb, leading leukemia experts, and real people who have been treated for ALL explore practical foundations for successful asparaginase therapy. Leveraging new consensus recommendations, faculty experts explain how to select and when to switch asparaginase formulations, how to monitor serum asparaginase activity, and strategies to mitigate key toxicities while avoiding early asparaginase discontinuation that can compromise survival. Real-world stories from young adults who have been treated for ALL highlight the stakes of getting this right and the challenges of access, adherence, and comprehensive care that clinicians can address in everyday practice.

Learning Goal/Purpose

The goal of this educational activity is to enhance the knowledge, competence, and confidence that hematology/oncology healthcare providers need to achieve better outcomes for young adults with ALL through more consistent application of pediatric-inspired regimens, optimized …

Drs. Jonathan Strober and Diana Castro examine the diagnostic approach to generalized myasthenia gravis (gMG), with a focus on age-related differences in clinical presentation. They describe early signs in pediatric patients—such as ptosis and impaired extraocular movements—and contrast these with the fluctuating fatigue, bulbar involvement, and proximal muscle weakness more commonly seen in adults. The discussion includes practical strategies for diagnostic confirmation and highlights the role of antibody testing and the limitations of electrophysiologic studies in children. The faculty emphasize the importance of keeping MG in the differential diagnosis to minimize delays in recognition and treatment.

This discussion between Drs. Diana Castro and Jonathan Strober focuses on the clinical utility of patient stratification and antibody profiling in generalized myasthenia gravis (gMG). The conversation addresses how age of onset, antibody status (acetylcholine receptor, MuSK, LRP4), and comorbidities can influence diagnosis and management plans. The speakers highlight the limitations of current pediatric assessment tools and the implications of antibody status for access to targeted therapies. Practical considerations for repeat testing, use of modified clinical scales, and individualized communication strategies with pediatric patients and families are also examined, emphasizing the nuanced approach required in younger populations.

Drs. Diana Castro and Jonathan Strober discuss treatment strategies for generalized myasthenia gravis (gMG), focusing on pediatric and adolescent care. They review traditional therapies and newer agents, such as FcRn and complement inhibitors, highlighting the role of antibody status and considerations for thymectomy. The conversation also addresses monitoring challenges, including limitations of clinical scales and the importance of patient and caregiver input in assessing treatment response.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.